Patents by Inventor Jorge Moscat

Jorge Moscat has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR TREATING SERRATED COLORECTAL CANCER
    Publication number: 20230364205
    Abstract: Disclosed herein are methods for identifying a subject as having serrated colorectal cancer (CRC), and models of human serrated CRC. Also provided herein are methods for treating serrated CRC in the subject.
    Type: Application
    Filed: March 19, 2021
    Publication date: November 16, 2023
    Inventors: Jorge Moscat-Guillen et al., Matia T. Diza-Meco Conde, Maria Angeles Duran-Molina, Yuki Nakanishi
  • Models and Methods Useful for the Treatment of Serrated Colorectal Cancer
    Publication number: 20220177561
    Abstract: Disclosed herein are methods for identifying a subject as having serrated colorectal cancer (CRC), and models of human serrated CRC. Also provided herein are methods for treating serrated CRC in the subject.
    Type: Application
    Filed: December 10, 2019
    Publication date: June 9, 2022
    Inventors: Jorge MOSCAT, Maria T. DIAZ-MECO, Angeles DURAN, Yuki NAKANISHI
  • P62 as a diagnostic tool for alzheimer's disease
    Patent number: 7608412
    Abstract: The p62 protein has been analyzed and identified as the significant contributor to several metabolic pathways that lead to metabolic syndrome, Alzheimer's Disease, and other related diseases. The absence of the p62 protein has a profound effect on the accumulation of tau protein, amyloid beta protein and an increase in blood insulin levels. The accumulation of tau protein and amyloid beta protein in neurological tissues is a hallmark of neurological metabolic diseases such as Alzheimer's Disease and related dementias. Moreover, increase blood insulin levels is an indicator of insulin resistance in mammals. Accordingly, the present invention provides a method for screening a mammal for metabolic disease comprising the step of detecting the absence of the p62 protein.
    Type: Grant
    Filed: October 5, 2006
    Date of Patent: October 27, 2009
    Assignee: Auburn University
    Inventors: Marie W. Wooten, Maria T. Diaz-Meco, Jorge Moscat
  • P62 AS A RISK DETERMINANT FOR METABOLIC SYNDROME
    Publication number: 20070238643
    Abstract: The p62 protein has been analyzed and identified as the significant contributor to several metabolic pathways that lead to metabolic syndrome, Alzheimer's Disease, and other related diseases. The absence of the p62 protein has a profound effect on the accumulation of tau protein, amyloid beta protein and an increase in blood insulin levels. The accumulation of tau protein and amyloid beta protein in neurological tissues is a hallmark of neurological metabolic diseases such as Alzheimer's Disease and related dementias. Moreover, increase blood insulin levels is an indicator of insulin resistance in mammals. Accordingly, the present invention provides a method for screening a mammal for metabolic disease comprising the step of detecting the absence of the p62 protein.
    Type: Application
    Filed: October 5, 2006
    Publication date: October 11, 2007
    Inventors: Marie Wooten, Maria Diaz-Meco, Jorge Moscat